Document Detail

B cell responses to HIV and the development of human monoclonal antibodies.
MedLine Citation:
PMID:  1572084     Owner:  NLM     Status:  MEDLINE    
In this review B cell responses in HIV-infected individuals are summarized together with the techniques used to date to produce human monoclonals to HIV and the properties of these antibodies. Profound disturbances in B cell responses are apparent both in vivo and in vitro. While there is evidence in vivo of marked polyclonal B cell activation, primary and secondary antibody responses are impaired. Similarly these cells exhibit spontaneous immunoglobulin secretion upon in vitro culture but do not readily respond to B cell mitogens and recall antigens including HIV. Furthermore, certain of these defects can be reproduced in normal B cells in vitro by incubation with HIV or HIV coded peptides. Individuals infected with HIV develop antibodies to HIV structural proteins (e.g. p17, p24, gp41 and gp120) and regulatory proteins (e.g. vif, nef, RT). Autoantibodies against a number of immunologically important molecules are also frequently observed. The anti-HIV antibodies are predominantly of the IgG1 isotype and exhibit a variety of effects on the virus in vitro. To date, using conventional immortalization strategies, an appreciable number of human monoclonals to HIV have been developed. These have been specific for gp41, gp120 and gag with antibodies of the former specificity predominating. The majority of these antibodies have been of the IgG1 isotype. Only a small number of the antibodies neutralize virus in vitro and most of these react with gp120. The neutralizing antibodies recognize conformational and carbohydrate epitopes or epitopes in amino acid positions 306-322. The predominant epitopes recognized by the anti-gp41 antibodies were in amino acid positions 579-620 and 644-662. A high percentage (congruent to 25%) of these antibodies enhance viral growth in vitro. The problems relating to the production of human monoclonals to HIV are discussed together with strategies that could be used in the future.
J E Boyd; K James
Related Documents :
9367864 - Construction and enhanced cytotoxicity of a [cyanovirin-n]-[pseudomonas exotoxin] conju...
21171874 - Control of hepatitis b in china: prevention and treatment.
21292884 - Drug resistance surveillance in resource-poor settings: current methods and considerati...
20209134 - Preserved mhc class ii antigen processing in monocytes from hiv-infected individuals.
7032234 - Igm deposition in skin biopsies from patients with primary biliary cirrhosis.
7635454 - Human herpesvirus type 6 and cytomegalovirus in aids-associated kaposi's sarcoma: no ev...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinical and experimental immunology     Volume:  88     ISSN:  0009-9104     ISO Abbreviation:  Clin. Exp. Immunol.     Publication Date:  1992 May 
Date Detail:
Created Date:  1992-06-02     Completed Date:  1992-06-02     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0057202     Medline TA:  Clin Exp Immunol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  189-202     Citation Subset:  IM; X    
Department of Surgery, University Medical School, Edinburgh, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / biosynthesis*
B-Lymphocytes / physiology*
Cell Line, Transformed
HIV / immunology*
HIV Antibodies / biosynthesis*
HIV Infections / immunology
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/HIV Antibodies

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Glutathione, protein sulfhydryls and cysteine proteases in gastric mucosal injury and protection.
Next Document:  Treatment of patients with chronic granulomatous disease with recombinant human interferon-gamma doe...